Rosacea
Conditions
Keywords
Rosacea, Bromonidine, intensed pulse light
Brief summary
This is an interventional and prospective study. The study is designed to evaluate the additional benefits of a combination of IPL treatment and local application of Bromonide 0.33% gel in the treatment of erythematotelangiectatic (ETR) and papulopustular (PPR).
Detailed description
Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. In addition half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
Interventions
DRUGBromonide 0.33% gel
Patients would be treated with full face application of bromonide 0.33% gel once daily for three months.
DEVICEIntense Pulsed Light (M22)
Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
Sponsors
Rabin Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Masking description
Physicians will perform assessment of clinical outcome, using clinical photographs .These physicians will be blinded to which half of the face was treated with intense pulsed light.
Intervention model description
This is an interventional, prospective single blinded study. Patients would be treated with full face application of bromonide 0.33% gel once daily for three months. In addition half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patient (male or female) must be over 18 yaers old of age and fulfil one of the following: 1. Suffer from ETR 2. Suffer from PPR 3. Suffer from a combination of ETR and PPR.
Exclusion criteria
* 1.Under 18 years old of age. 2.Pregnant women. 3.Systemic treatment of rosacea at the previous six months before enrollment. 4.Topical treatment of rosacea at the previous one month before enrollment. 5.Phymatous or occular rosacae.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| patient self-assessment questionaires score change | three months after initiation of treatment compared to Baseline | Patient will assess disease change on 5 points scale (0=no improvement, 1=0-25% improvement, 2=26-49% improvement, 3=50-74% improvement, 4= 75-100% improvement. |
| Physicians' unblinded score assessment | three months after initiation of treatment compared to Baseline | Physician will assess disease change on 5 points scale (0=no improvement, 1=0-25% improvement, 2=26-49% improvement, 3=50-74% improvement, 4= 75-100% improvement. |
Countries
Israel
Outcome results
None listed